Get the Stockscreener App
4.93
4.01%
0.19
After Hours:
4.96
0.03
+0.61%
Precigen Inc stock is traded at $4.93, with a volume of 2.40M.
It is up +4.01% in the last 24 hours and up +18.23% over the past month.
Precigen Inc is a biotechnology company that develops synthetic biology solutions. The company designs build and regulate gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. Its reportable segments are Biopharmaceuticals and Exemplar. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs.
See More
Previous Close:
$4.74
Open:
$4.79
24h Volume:
2.40M
Relative Volume:
0.55
Market Cap:
$1.74B
Revenue:
$6.23M
Net Income/Loss:
$-95.90M
P/E Ratio:
-12.64
EPS:
-0.39
Net Cash Flow:
$-68.47M
1W Performance:
+14.92%
1M Performance:
+18.23%
6M Performance:
+158.12%
1Y Performance:
+148.99%
1-Day Range:
$4.68
$4.95
1-Week Range:
$4.12
$5.00
52-Week Range:
$1.11
$5.225
Precigen Inc Stock (PGEN) Company Profile
Name
Precigen Inc
Sector
Industry
Phone
301-556-9900
Address
20374 SENECA MEADOWS PARKWAY, GERMANTOWN, MD
Compare PGEN vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PGEN
Precigen Inc
|
4.93 | 1.68B | 6.23M | -95.90M | -68.47M | -0.39 |
|
VRTX
Vertex Pharmaceuticals Inc
|
491.47 | 117.98B | 12.04B | 3.95B | 3.34B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
803.17 | 82.85B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
821.96 | 51.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.40 | 40.75B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.07 | 38.33B | 4.98B | 69.60M | 525.67M | 0.5198 |
Precigen Inc Stock (PGEN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-15-25 | Upgrade | JP Morgan | Underweight → Neutral |
| Mar-22-24 | Downgrade | JP Morgan | Neutral → Underweight |
| May-23-23 | Initiated | JP Morgan | Neutral |
| Nov-18-22 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-25-21 | Initiated | Stifel | Buy |
| Feb-22-21 | Initiated | Wells Fargo | Overweight |
| Feb-18-21 | Initiated | B. Riley Securities | Buy |
| May-08-20 | Initiated | H.C. Wainwright | Buy |
View All
Precigen Inc Stock (PGEN) Latest News
Precigen, Inc. (PGEN) Builds Commercial Stage With Global Regulatory Support - Insider Monkey
Goldman Sachs Penny Stocks: Top 12 Stock Picks - Insider Monkey
Precigen, Inc. (PGEN) Stock Analysis: Exploring a Promising 79% Upside Potential in Biotechnology - DirectorsTalk Interviews
Take Profit: Can Precigen Inc beat the S P 500Insider Buying & Consistent Income Trade Ideas - baoquankhu1.vn
Gains Recap: Is Planet Labs PBC stock a buy or sell2025 Market Outlook & Daily Growth Stock Tips - baoquankhu1.vn
Precigen: PAPZIMEOS Is Delivering For This Under-The-Radar Biotech (NASDAQ:PGEN) - Seeking Alpha
What are Precigen Inc.’s growth levers2025 Bull vs Bear & Expert Curated Trade Setups - mfd.ru
Precigen, Inc. (NASDAQ:PGEN) Receives Average Recommendation of "Hold" from Brokerages - MarketBeat
Risk Hedge: What is the dividend yield of Precigen IncJuly 2025 Closing Moves & Weekly Top Gainers Trade List - baoquankhu1.vn
Precigen, Inc. (PGEN) Stock Analysis: Unpacking The 100% Upside Potential - DirectorsTalk Interviews
Market Trends: Is Precigen Inc stock risky to hold nowTrade Ideas & Community Shared Stock Ideas - baoquankhu1.vn
Precigen (PGEN) Is Down 5.7% After Consensus Backs PAPZIMEOS As New First-Line RRP Therapy - simplywall.st
AI Stocks: Can Bioceres Crop Solutions Corp outperform under higher oil pricesMarket Trend Summary & Safe Capital Growth Stock Tips - baoquankhu1.vn
Precigen, Inc. (PGEN) Stock Analysis: 87% Upside Potential Ignites Investor Interest - DirectorsTalk Interviews
Institutional Investors May Overlook Precigen, Inc.'s (NASDAQ:PGEN) Recent US$110m Market Cap Drop as Long-term Gains Remain Positive - 富途牛牛
Precigen to Announce Second Quarter and First Half 2022 Financial Results on August 8th - Nasdaq
Zacks Research Downgrades Precigen (NASDAQ:PGEN) to Strong Sell - MarketBeat
Precigen, Inc. (PGEN) Stock Analysis: Exploring a Potential 75% Upside in the Biotech Sector - DirectorsTalk Interviews
Market Pulse: Is Precigen Inc stock influenced by commodity pricesJuly 2025 Setups & Free Daily Entry Point Trade Alerts - baoquankhu1.vn
Why Precigen (PGEN) Is Up 5.3% After PAPZIMEOS Becomes First-Line RRP Standard of Care – And What's Next - simplywall.st
Patient Capital Management LLC Grows Stake in Precigen, Inc. $PGEN - MarketBeat
New Expert Consensus Published in The Laryngoscope Recommends PAPZIMEOS (zopapogene imadenovec) as the New Standard of Care First-Line Treatment for Adults with Recurrent Respiratory Papillomatosis - Finviz
New expert consensus shifts RRP treatment from surgery to PAPZIMEOS - Stock Titan
3 Growth Companies With High Insider Ownership And Up To 79% Earnings Growth - simplywall.st
Precigen, Inc. (NASDAQ:PGEN) Sees Large Growth in Short Interest - MarketBeat
Earnings Risk: Is Precigen Inc stock influenced by commodity prices2025 Price Targets & Low Volatility Stock Recommendations - baoquankhu1.vn
Precigen (NASDAQ:PGEN) Shares Gap UpWhat's Next? - MarketBeat
Precigen, Inc. (NASDAQ:PGEN) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Assessing Precigen (PGEN) Valuation After PAPZIMEOS Commercial Momentum And EMA Milestone - Sahm
Is PGEN’s PAPZIMEOS Exclusivity Quietly Redefining Its Competitive Moat in Rare Disease Therapy? - simplywall.st
Precigen reports strong adoption of RRP treatment PAPZIMEOS By Investing.com - Investing.com Nigeria
Precigen to Present at the 44th Annual J.P. Morgan Healthcare Conference - Investing News Network
Precigen (NASDAQ:PGEN) Trading Down 7.5%What's Next? - MarketBeat
Precigen reports strong adoption of RRP treatment PAPZIMEOS - Investing.com
Precigen Showcases Rapid Commercialization Momentum and Growing Market Adoption of First-and-Only FDA-Approved Therapy for RRP at the 44th Annual J.P. Morgan Healthcare Conference - marketscreener.com
Iridian Asset Management LLC CT Sells 611,716 Shares of Precigen, Inc. $PGEN - MarketBeat
New RRP treatment spreads nationwide as more insurers agree to cover it - Stock Titan
Is Precigen Inc. stock a buy on dipsInsider Buying & Technical Analysis for Trade Confirmation - ulpravda.ru
Precigen, Inc. (PGEN) Stock Analysis: Biotechnology Innovator With Potential 84% Upside - DirectorsTalk Interviews
Can Precigen Inc. stock beat market expectations this quarterJuly 2025 Review & Fast Moving Stock Trade Plans - ulpravda.ru
Can Precigen Inc. stock double in next 5 yearsMarket Weekly Review & Fast Exit and Entry Strategy Plans - ulpravda.ru
Precigen, Inc. (NASDAQ:PGEN): Are Analysts Optimistic? - simplywall.st
Market Sentiment Around Loss-Making Precigen, Inc. (NASDAQ:PGEN) - 富途牛牛
Is Precigen Inc. stock a buy before product launchesMorning Star Patterns & Start Small. End Wealthy. - ulpravda.ru
Will Precigen Inc. stock recover faster than peersGeopolitical Risk Analysis & Amplify Gains With Picks - ulpravda.ru
Will Precigen Inc. stock see insider buying2026 world cup usa national team quarterfinals star players possession football tactical prediction insights - ulpravda.ru
Precigen to Present at the 44th Annual J.P. Morgan Healthcare Co - GuruFocus
Precigen (NASDAQ:PGEN) Trading Down 6.1%What's Next? - MarketBeat
Precigen (NASDAQ:PGEN) Trading Down 4.2%Here's What Happened - MarketBeat
Will PGEN’s New Drug Make a Splash? - StocksToTrade
Precigen Inc Stock (PGEN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.12%
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):